NFE2L2 and glioblastoma: At both the single-cell and bulk levels, consistent aberrant expression of CYBB and SOD2 indicated high Nrf2 activation, and both CYBB and SOD2 were differentially expressed in mesenchymal GBM cells and linked to treatment resistance.